BlackRock
RUBY

BlackRock’s Rubius Therapeutics, Inc RUBY Stock Holding History

BlackRock’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,197,501
Closed -$210K – 5784
2022
Q4 		$210K Sell
1,197,501
-390,426
-25% -$107K ﹤0.01% 4843
2022
Q3 		$688K Buy
1,587,927
+161,695
+11% +$121K ﹤0.01% 4624
2022
Q2 		$1.21M Sell
1,426,232
-2,080,337
-59% -$3.49M ﹤0.01% 4461
2022
Q1 		$19.3M Buy
3,506,569
+24,768
+0.7% +$157K ﹤0.01% 3190
2021
Q4 		$33.7M Sell
3,481,801
-2,679
-0.1% -$37.1K ﹤0.01% 2943
2021
Q3 		$62.3M Buy
3,484,480
+48,645
+1% +$1.06M ﹤0.01% 2516
2021
Q2 		$83.9M Sell
3,435,835
-201,782
-6% -$5.05M ﹤0.01% 2364
2021
Q1 		$96.4M Buy
3,637,617
+390,894
+12% +$5.71M ﹤0.01% 2210
2020
Q4 		$24.6M Sell
3,246,723
-40,704
-1% -$242K ﹤0.01% 2899
2020
Q3 		$16.5M Sell
3,287,427
-54,717
-2% -$290K ﹤0.01% 2967
2020
Q2 		$20M Buy
3,342,144
+324,154
+11% +$1.91M ﹤0.01% 2793
2020
Q1 		$13.4M Sell
3,017,990
-86,651
-3% -$643K ﹤0.01% 2830
2019
Q4 		$29.5M Sell
3,104,641
-73,451
-2% -$711K ﹤0.01% 2669
2019
Q3 		$24.9M Buy
3,178,092
+383,401
+14% +$4.47M ﹤0.01% 2691
2019
Q2 		$44M Buy
2,794,691
+130,641
+5% +$2.11M ﹤0.01% 2393
2019
Q1 		$48.2M Buy
2,664,050
+233,545
+10% +$3.58M ﹤0.01% 2296
2018
Q4 		$39.1M Buy
2,430,505
+840,707
+53% +$15.3M ﹤0.01% 2378
2018
Q3 		$38.2M Buy
+1,589,798
New +$36.3M ﹤0.01% 2527

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

BlackRock's RUBY Position: Q1 2023 in Review

BlackRock sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 1,197,501 shares — an estimated $210K sold.

BlackRock first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $96.4M in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • BlackRock reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • BlackRock sold 1,197,501 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $210K.
  • BlackRock first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • BlackRock's Rubius Therapeutics, Inc position peaked at $96.4M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.